Euro advisory group back Bristol-Myers’ Empliciti combo for multiple myeloma

The European Medicines Agency’s advisory group CHMP has adopted a positive opinion backing approval of Bristol-Myers Squibb’s (NYSE:BMY) Empliciti (elotuzumab) plus Celgene’s (NASDAQ:CELG) Pomalyst (pomalidomide) and low-dose dexamethasone for the treatment of adults patients with relapsed/refractory multiple myeloma who have received at least two prior lines of therapy, including Celgene’s Revlimid (lenalidomide) and a protease inhibitor, and have experienced cancer progression on the last therapy.

A final decision from the European Commission usually takes ~60 days.

https://seekingalpha.com/news/3482222-european-advisory-group-back-bristol-myers-empliciti-combo-multiple-myeloma